Analysts Offer Insights on Healthcare Companies: Alere Inc (NYSE: ALR), Agilent (NYSE: A) and Viewray (NASDAQ: VRAY)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alere Inc (NYSE: ALR), Agilent (NYSE: A) and Viewray (NASDAQ: VRAY).

Alere Inc (NYSE: ALR)

BTIG analyst Dane Leone reiterated a Hold rating on Alere Inc (NYSE: ALR) on May 22. The company’s shares closed yesterday at $48.85, close to its 52-week high of $49.53.

Leone wrote:

“Continued Growth in Infectious Disease Business Yesterday, Alere filed its preliminary unaudited 10-K and proxy statements following review of matters in South Korea and Japan, and expects to file their Form 10-K by June 15th, 2017. The preliminary financial statements included 4Q16 and FY2016 results, as well as re- statements for revenue recognition during 2014, 2015, and 2016. Topline preliminary 1Q17 financial results were also provided. The filing of the proxy indicates a decoupling process versus the 10-K filing, allowing the shareholder meeting to likely occur between mid-to-late July. The company must resolve outstanding accounting issues and file the 10K by June 15 th or face another negotiation with the creditors and bond holders. We remain Neutral as we continue to think that the deal with Abbott (ABT, Buy, $50PT) will close at the stated terms of $51 per share later this year.”

According to TipRanks.com, Leone is a 5-star analyst with an average return of 12.9% and a 71.0% success rate. Leone covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Quest Diagnostics Inc, and Trillium Therapeutics.

Alere Inc has an analyst consensus of Moderate Buy, with a price target consensus of $51.

Agilent (NYSE: A)

BTIG analyst Karen Koski reiterated a Buy rating on Agilent (NYSE: A) yesterday and set a price target of $65. The company’s shares closed yesterday at $58.66, close to its 52-week high of $59.98.

Koski said:

“While we were bullish on shares into the print, Agilent made exceeding our above-guidance core revenue growth and adjusted EPS projections for F2Q17 look easy.”

According to TipRanks.com, Koski is a 4-star analyst with an average return of 9.4% and a 62.4% success rate. Koski covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Orasure Technologies, and Foundation Medicine.

Currently, the analyst consensus on Agilent is Strong Buy and the average price target is $64.33, representing a 9.7% upside.

In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $66 price target.
Viewray (NASDAQ: VRAY)

In a report released yesterday, Sean Lavin from BTIG reiterated a Buy rating on Viewray (NASDAQ: VRAY), with a price target of $10. The company’s shares closed yesterday at $6.45.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 10.2% and a 56.9% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Obalon Therapeutics Inc.

Currently, the analyst consensus on Viewray is Strong Buy and the average price target is $9.33, representing a 44.7% upside.

In a report issued on May 16, Aegis Capital also reiterated a Buy rating on the stock with a $11 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.